Aligos Therapeutics (ALGS) AI Stock Analysis

• Market Cap: $66.07M
• Dividend Yield: N/A
• Average Volume (3M): 68.12K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.79
• Revenue Growth: -60.16%
• EPS Growth: N/A
• Country: US
• Employees: 70
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -1.53
• Shares Outstanding: 5,351,374
• 10 Day Avg. Volume: 89,204
• 30 Day Avg. Volume: 68,121
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.63
• Enterprise Value/Revenue: -13.09
• Enterprise Value/Gross Profit: -18.51
• Enterprise Value/Ebitda: 0.57
• 1Y Price Target: $50.00
• Price Target Upside: 340.92% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 45 Neutral
• Price Target: $8.50 ▼(-25.04% Downside)

Aligos Therapeutics' overall stock score is primarily impacted by its poor financial performance, characterized by ongoing losses and negative cash flows. Technical analysis provides some short-term bullish signals, but the long-term trend remains bearish. The valuation reflects the company's lack of profitability, with a negative P/E ratio. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Clinical Milestones

With written regulatory guidance and a global Phase 2 trial underway, ALG-000184 has a de-risked path to approval and potential to redefine the chronic HBV treatment landscape.

Product Potential

ALG-000184 has the potential to become the new standard-of-care for chronic suppression of hepatitis B virus (HBV), serving as the oral backbone to future functional cure regimens.

Safety and Efficacy

ALG-000184's effects were robust in HBeAg-negative CHB patients, leading to rapid and significant reductions in HBV DNA and HBV RNA while maintaining a favorable safety profile.

Negative Factors

Regulatory Challenges

The initiation of ALG-000184's randomized, double-blind, active-controlled Phase 2 study is regarded as Aligos' next major milestone.

Aligos Therapeutics Business Overview & Revenue Model

Company Description

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

How the Company Makes Money

Aligos Therapeutics generates revenue primarily through research and development partnerships, licensing agreements, and collaboration with other pharmaceutical companies. These partnerships often involve upfront payments, milestone payments based on the achievement of specific development goals, and royalties on future sales of successfully commercialized products. Aligos also seeks funding from government grants and other sources to support its clinical trials and research initiatives. The company’s financial performance is closely tied to the progress and outcomes of its clinical trials, regulatory approvals, and the commercial success of its developed therapies.

Aligos Therapeutics Financial Statement Overview

Summary

Aligos Therapeutics faces significant challenges in profitability, with consistent losses and negative cash flows, typical for an early-stage biotech firm focusing on research and development. The company's balance sheet is relatively robust with low leverage, providing stability. However, the ongoing cash burn rate and negative profitability metrics pose risks that need to be managed strategically.

Income Statement

Aligos Therapeutics shows a volatile revenue pattern with a decline to $3.27M in TTM from $15.53M in 2023. Despite improving gross profit margins, ongoing losses with a net profit margin of -1628% in TTM highlight persistent challenges in achieving profitability. The EBIT and EBITDA margins also remain negative, indicating operational inefficiencies.

Balance Sheet

The balance sheet indicates a relatively stable equity position with stockholders' equity at $116.45M, although the negative net income affects ROE. The debt-to-equity ratio of 0.07 suggests low leverage, which is favorable, but the negative equity in previous years is a concern. The equity ratio stands at 77%, reflecting a strong asset base.

Cash Flow

Cash flow analysis reveals negative operating cash flow of -$78.91M, with free cash flow remaining negative at -$79.01M. However, strong financing cash flow at $102.12M in TTM supports liquidity. The operating cash flow to net income ratio shows inefficiency in converting net income to cash, a risk for future operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.17M	3.94M	15.53M	13.91M	4.36M	0.00
Gross Profit	2.24M	3.94M	12.46M	10.23M	-99.79M	-3.33M
EBITDA	-73.51M	-89.15M	-85.06M	-93.91M	-124.54M	-105.06M
Net Income	-74.18M	-131.21M	-87.68M	-96.05M	-128.33M	-108.54M
Balance Sheet
Total Assets	134.71M	70.09M	151.53M	146.69M	235.37M	265.30M
Cash, Cash Equivalents and Short-Term Investments	123.06M	56.94M	135.70M	125.83M	190.73M	243.51M
Total Debt	6.88M	8.38M	11.14M	12.57M	14.46M	13.01M
Total Liabilities	32.84M	99.07M	59.45M	42.79M	50.64M	45.26M
Stockholders Equity	101.87M	-28.97M	92.08M	103.90M	184.73M	220.04M
Cash Flow
Free Cash Flow	-75.12M	-80.87M	-79.02M	-80.33M	-116.55M	-76.33M
Operating Cash Flow	-74.92M	-80.74M	-79.00M	-79.39M	-115.66M	-74.26M
Investing Cash Flow	-53.12M	-18.28M	44.98M	-26.29M	3.02M	32.76M
Financing Cash Flow	101.66M	355.00K	88.33M	164.00K	78.68M	192.35M

Aligos Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.34
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALGS, the sentiment is Positive. The current price of 11.34 is above the 20-day moving average (MA) of 9.33, above the 50-day MA of 8.65, and below the 200-day MA of 15.16, indicating a neutral trend. The MACD of 0.75 indicates Negative momentum. The RSI at 66.39 is Neutral, neither overbought nor oversold. The STOCH value of 66.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ALGS.

Aligos Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.92B	-0.43	-41.67%	2.21%	22.29%	-1.85%
TVRD	50 Neutral	$285.45M	―	-93.85%	―	-40.16%	78.28%
GBIO	50 Neutral	$38.93M	―	-85.45%	―	61.15%	54.71%
ALGS	45 Neutral	$66.07M	―	-87.74%	―	-60.16%	―
PYPD	41 Neutral	$34.65M	―	-312.77%	―	―	61.18%
ANVS	35 Underperform	$44.43M	―	-365.03%	―	―	54.85%
NRSN	30 Underperform	$27.06M	―	-2880.11%	―	―	31.09%

Aligos Therapeutics Corporate Events

Aligos Therapeutics Approves Major Amendments at Annual Meeting

On June 25, 2025, Aligos Therapeutics, Inc. held its Annual Meeting of Stockholders where significant amendments to the company’s Certificate of Incorporation were approved. These amendments included increasing the number of authorized shares of voting common stock from 20 million to 100 million and non-voting common stock from 800,000 to 15.8 million. These changes, effective immediately upon filing with the Secretary of State of Delaware, are expected to impact the company’s capital structure significantly. Additionally, stockholders voted on five proposals, including electing three Class II directors and ratifying Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.